CompletedNCT00567034
Naltrexone added to olanzapine for metabolic side effects
About this title
Read the official source — NCT00567034Medication studyAges 21–55United StatesSchizophrenia
Understand this study
Who was this study for?
Listed age limits: 21 years to 55 years.
- Listed locations
- BelmontSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateDecember 2006
- Recruitment status
- Completed
- Enrollment listed in the registry
- 30
- Sponsor
- Mclean Hospital
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States
- Age range
- From 21 Years to 55 Years
- Official registry ID
- NCT00567034
- Official title
Show the full official title
Augmenting Zyprexa With Naltrexone: Normalization of the Weight Gain Side Effect and the CNS Reward and Sensory Function
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Belmont
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Mclean Hospital, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including naltrexone and placebo.
Who was this study for?
Listed age limits: 21 years to 55 years.
Want to explore more studies?
Explore studiesRelated studies
Paliperidone Injections Compared With Oral Medication for Schizophrenia
18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia